Recently Funded Post-IPO Debt Biotechnology Startups
Updated Sep 2026
There are 90 funded Post-IPO Debt Biotechnology startups in the FundedIQ database, each with its funding rounds, amounts, investors, industries, locations and company details. This page provides an overview of the Post-IPO Debt Biotechnology startup funding landscape, along with the 90 most recently funded Post-IPO Debt Biotechnology startups.
New York and Cambridge hold the deepest concentrations of these companies.
Capital concentration favors New York and Cambridge. While activity spans several nations, the United States dominates the map. Working this segment means focusing on a few key cities rather than a broad search. This geographic clustering simplifies outreach for those targeting the biotechnology sector via debt instruments.
Post-IPO Debt Biotechnology funded startup statistics
Funded Post-IPO Debt Biotechnology startups
90
tracked in the database
Most recent funding round on record: Oct 2022.
90 most recently funded Post-IPO Debt Biotechnology startups
90 shownOrdered by the date of the latest funding round. Each row gives the company, its location and industry, what it does, the stage and date of that round, and the disclosed amount.
Company
What they do
Latest round
Amount
A
Awakn Life Sciences
Toronto, Canada · Biotechnology
Awakn Life Sciences is a biotechnology company with clinical operations that develops and delivers…
Post-IPO Debt ·
$570k
B
BerGenBio
Bergen, Norway · Biotechnology
Post-IPO Debt ·
$9.5M
I
Insmed
Bridgewater, United States · Biotechnology
Post-IPO Debt ·
$500M
V
Verona Pharma
London, United Kingdom · Biotechnology
Post-IPO Debt ·
$150M
T
Thermo Fisher Scientific
Waltham, United States · Biotechnology
Post-IPO Debt ·
$741M
R
Replimune Group
Woburn, United States · Biotechnology
Replimune Group develop the next generation of ‘oncolytic immunotherapies’ for the treatment of cancer.…
Post-IPO Debt ·
$200M
B
BioHarvest Sciences
Vancouver, Canada · Biotechnology
BioHarvest Sciences produces and sells a food-based nutraceutical product called ViniaTM. It is the first and…
Post-IPO Debt ·
$7.3M
H
HLS Therapeutics
Caledon, Canada · Biotechnology
Post-IPO Debt ·
$91M
S
Spectrum Pharmaceuticals
Henderson, United States · Biotechnology
Spectrum Pharmaceuticals is a commercial-stage biotechnology company with fully integrated commercial and…
Post-IPO Debt ·
$30M
M
Medtronic
Minneapolis, United States · Biotechnology
Medtronic develops healthcare technology to treat chronic diseases. Its medical technology is providing…
Post-IPO Debt ·
$3.5B
V
VBI Vaccines
Cambridge, United States · Biotechnology
VBI Vaccines is a biopharmaceutical company developing novel technologies that seek to expand vaccine…
Post-IPO Debt ·
$100M
A
Alnylam Pharmaceuticals
Cambridge, United States · Biotechnology
Alnylam is the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the…
Post-IPO Debt ·
$900M
A
Adaptive Biotechnologies
Seattle, United States · Biotechnology
Adaptive Biotechnologies is a commercial-stage company advancing the field of immune-driven medicine by…
Post-IPO Debt ·
$125M
B
Brighter
Kista, Sweden · Biotechnology
Data-driven solutions for smarter treatment of chronic conditions. Brighter is a health-tech company from…
Post-IPO Debt ·
$10M
P
PDS Biotechnology Corporation
North Brunswick, United States · Biotechnology
PDS Biotechnology Corporation is a biopharmaceutical company. It develops immunotherapies for cancer and…
Post-IPO Debt ·
$25M
K
Kinarus Therapeutics (SIX:KNRS)
Basel, Switzerland · Biotechnology
Kinarus is a biopharmaceutical company that develops differentiated medicines in areas of stress related…
Post-IPO Debt ·
$21M
A
ATAI Life Sciences
Munich, Germany · Biotechnology
ATAI is a global biotech company builder that leverages a decentralized, technology- and data-driven platform…
Post-IPO Debt ·
$175M
O
Opthea
South Yarra, Australia · Biotechnology
Opthea Limited, previously known as Circadian Technologies, is an Australian biotechnology company that is…
Post-IPO Debt ·
$170M
C
Cerevel Therapeutics
Boston, United States · Biotechnology
Cerevel Therapeutics is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases.…
Post-IPO Debt ·
$300M
T
Tetra Bio-Pharma
Ottawa, Canada · Biotechnology
Tetra Bio-Pharma is a biopharmaceutical company that focuses on cannabinoid-based drug discovery and…
Post-IPO Debt ·
$6.0M
C
Clearside Biomedical
Alpharetta, United States · Biotechnology
Clearside BioMedical, an ophthalmic company, specializes in the research, development, and commercialization…
Post-IPO Debt ·
$65M
R
Rani Therapeutics
San Jose, United States · Biotechnology
Rani Therapeutics is a clinical-stage biotech company that has developed a platform technology to enable oral…
Post-IPO Debt ·
$45M
M
MeiraGTx
New York, United States · Biotechnology
MeiraGTx is committed to the development and commercialization of innovative gene therapy products to…
Post-IPO Debt ·
$75M
N
Neuroone Medical Technologies
Eden Prairie, United States · Biotechnology
NeuroOne Medical Technologies Corporation is a developmental stage company committed to providing minimally…
Post-IPO Debt ·
$11M
M
MDxHealth
Irvine, United States · Biotechnology
MDxHealth is a molecular diagnostics company that develops and commercializes advanced epigenetic tests for…
Post-IPO Debt ·
$35M
V
Valeo Pharma
Kirkland, Canada · Biotechnology
Valeo Pharma is devoted to providing healthcare professionals and patients with the highest quality specialty…
Post-IPO Debt ·
$40M
E
Elevation Oncology
New York, United States · Biotechnology
Height Oncology makes genomic tests noteworthy by specifically creating medications to hinder the particular…
Post-IPO Debt ·
$50M
T
Theratechnologies
Montréal, Canada · Biotechnology
Theratechnologies Inc., a biopharmaceutical organization, takes part in the revelation of restorative items…
Post-IPO Debt ·
$40M
G
Galectin Therapeutics
Norcross, United States · Biotechnology
Galectin Therapeutics is applying its administration in galectin science and medication improvement to make…
Post-IPO Debt ·
$60M
I
IVERIC bio
Princeton, United States · Biotechnology
IVERIC bio is a science-driven biopharmaceutical organization zeroed in on the revelation and improvement of…
Post-IPO Debt ·
$250M
G
Gritstone Bio
Emeryville, United States · Biotechnology
Gritstone Oncology is a clinical-stage biotech organization creating growth explicit disease immunotherapies…
Post-IPO Debt ·
$80M
S
Sequana Medical
Zürich, Switzerland · Biotechnology
Sequana Medical is a Swiss medical device company providing implantable pump systems to manage fluid balance…
Post-IPO Debt ·
$10M
A
Arch Therapeutics
Natick, United States · Biotechnology
Curve Therapeutics, Inc. is a biotechnology organization fostering a clever way to deal with quit dying…
Post-IPO Debt ·
$3.5M
C
Cytokinetics
South San Francisco, United States · Biotechnology
Cytokinetics is a late-stage biopharmaceutical organization zeroed in on finding, creating and…
Post-IPO Debt ·
$450M
S
SQI Diagnostics
Toronto, Canada · Biotechnology
SQI Diagnostics is a medical systems company that develops proprietary technologies in multiplexing,…
Post-IPO Debt ·
$4.1M
A
Akero Therapeutics
Cambridge, United States · Biotechnology
Akero Therapeutics is dedicated to providing effective treatment options for individuals suffering from…
Post-IPO Debt ·
$100M
J
Juva Life
San Jose, United States · Biotechnology
Juva Life gets a profundity of information the science and restorative impacts of pot. Their in an upward…
Post-IPO Debt ·
$12M
E
Eiger BioPharmaceuticals
San Carlos, United States · Biotechnology
Eiger BioPharmaceuticals is a secretly held biotechnology organization that fosters a clever antiviral…
Post-IPO Debt ·
$75M
I
Inventiva Pharma
Daix, France · Biotechnology
Inventiva Pharma is a biopharmaceutical company in the clinical stage that focuses on creating oral small…
Post-IPO Debt ·
$52M
M
Madrigal Pharmaceuticals
Conshohocken, United States · Biotechnology
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a clinical-stage biopharmaceutical company pursuing novel…
Post-IPO Debt ·
$250M
T
The Green Organic Dutchman Holdings
Ancaster, Canada · Biotechnology
The Green Organic Dutchman Holdings Ltd. is a research & development company licensed under the Access to…
Post-IPO Debt ·
$3.1M
V
Valneva
Saint-herblain, France · Biotechnology
Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic…
Post-IPO Debt ·
$20M
H
Hemostemix
Blackfalds, Canada · Biotechnology
Hemostemix Inc. is a Canadian biotechnology company that specializes in creating blood-derived cell therapies…
Post-IPO Debt ·
$2.8M
P
Perrigo
Dublin, Ireland · Biotechnology
Perrigo Company plc is a leading global healthcare supplier that develops, manufactures and distributes…
Post-IPO Debt ·
$2.6B
P
PolyPid
Petah Tiqva, Israel · Biotechnology
PolyPid is a company in the development stage that has created a platform technology for the healthcare…
Post-IPO Debt ·
$15M
O
Oncorus
Cambridge, United States · Biotechnology
Oncorus, Inc. is a lean early-stage biotechnology company developing a next-generation immunotherapy platform…
Post-IPO Debt ·
$20M
V
Viridian Therapeutics
Boulder, United States · Biotechnology
Viridian Therapeutics is a biotechnology company advancing new treatments for patients with diseases that are…
Post-IPO Debt ·
$75M
V
Verastem Oncology
Needham, United States · Biotechnology
Verastem Oncology is a biopharmaceutical company committed to the development and commercialization of…
Post-IPO Debt ·
$25M
A
ADMA Biologics
Ramsey, United States · Biotechnology
ADMA is a specialty immune globulin company that develops, manufactures and intends to market plasma-based…
Post-IPO Debt ·
$150M
A
Ascendis Pharma
Palo Alto, United States · Biotechnology
Ascendis Pharma has built a high value pipeline with the aim of changing clinical treatment paradigms. Using…
Post-IPO Debt ·
$500M
L
Lexicon Pharmaceuticals
The Woodlands, United States · Biotechnology
Vocabulary Pharmaceuticals, Inc. (previously Lexicon Genetic) a biopharmaceutical organization, centers…
Post-IPO Debt ·
$150M
E
EyePoint Pharmaceuticals
Watertown, United States · Biotechnology
EyePoint Pharmaceuticals develops tiny, sustained-release drug delivery products designed to deliver drugs at…
Post-IPO Debt ·
$45M
M
Mustang Bio
New York, United States · Biotechnology
Mustang Bio is a biopharmaceutical company in the clinical stage that concentrates on obtaining, creating,…
Post-IPO Debt ·
$75M
T
Travere Therapeutics
San Diego, United States · Biotechnology
Travere Therapeutics is advancing therapeutic candidates for rare disorders in nephrology, hepatology and…
Post-IPO Debt ·
$275M
U
UroGen Pharma
New York, United States · Biotechnology
UroGen Pharma (formerly Theracoat ) (“UroGen” or “the Company”) is a clinical-stage biopharmaceutical company…
Post-IPO Debt ·
$100M
A
Acer Therapeutics
Newton, United States · Biotechnology
Acer Therapeutics is a pharmaceutical company that focuses on the acquisition, development, and…
Post-IPO Debt ·
$49M
I
Innoviva
Brisbane, United States · Biotechnology
Innoviva is committed to building long-lasting value and improving patient care, by partnering with companies…
Post-IPO Debt ·
$225M
C
Candel Therapeutics
Needham, United States · Biotechnology
Candel develops cancer immunotherapies designed to improve the lives of cancer patients and their families.…
Post-IPO Debt ·
$25M
A
Ardelyx
Fremont, United States · Biotechnology
Ardelyx develops novel, first-in-class oral therapeutics to correct mineral metabolism and metabolic…
Post-IPO Debt ·
$28M
Z
Zosano Pharma
Fremont, United States · Biotechnology
Zosano Pharma focuses on creating better products with its innovative drug delivery technology. Zosano's…
Post-IPO Debt ·
$15M
L
Lucira Health
Emeryville, United States · Biotechnology
Lucira Health is a medical technology company focused on the development and commercialization of…
Post-IPO Debt ·
$80M
C
Canntab Therapeutics
Markham, Canada · Biotechnology
Canntab Therapeutics Ltd is a biopharmaceutical company that aims at manufacturing & distributing hard pill…
Post-IPO Debt ·
$1.0M
C
Centogene
Rostock, Germany · Biotechnology
CENTOGENE is one of the largest genetic biotech companies worldwide, the European market leader, and one of…
Post-IPO Debt ·
$45M
T
Trinity Biotech
Bray, Ireland · Biotechnology
Trinity Biotech has actively pursued the aim of becoming a leading player in the international diagnostics…
Post-IPO Debt ·
$81M
S
Sierra Oncology
Vancouver, Canada · Biotechnology
Sierra Oncology is a late-stage biopharmaceutical company on a mission to deliver targeted therapies that…
Post-IPO Debt ·
$125M
C
Coherus Biosciences
Redwood City, United States · Biotechnology
Coherus Biosciences is a biopharmaceutical company that engages in the development, manufacture, and…
Post-IPO Debt ·
$100M
L
Liquidia Technologies
Morrisville, United States · Biotechnology
Liquidia Technologies is a late-stage clinical biopharmaceutical company focused on the development and…
Post-IPO Debt ·
$20M
I
Innate Pharma
Marseille, France · Biotechnology
Innate Pharma S.A. is a biopharmaceutical company that is creating new immunotherapy drugs for cancer and…
Post-IPO Debt ·
$33M
T
TG Therapeutics
New York, United States · Biotechnology
TG Therapeutics is an innovative, clinical-stage biopharmaceutical company focused on the acquisition,…
Post-IPO Debt ·
$70M
N
Noxxon Pharma
Berlin, Germany · Biotechnology
NOXXON Pharma AG, a biopharmaceutical company, develops biostable aptamers and substances based on mirror…
Post-IPO Debt ·
$19M
B
Biotricity
Redwood City, United States · Biotechnology
Biotricity is a medical technology company focused on delivering innovative, remote biometric monitoring…
Post-IPO Debt ·
$12M
E
Evolva
Reinach, Switzerland · Biotechnology
Evolva was founded in 2004 around a distinctive, proprietary, technology platform that uses synthetic biology…
Post-IPO Debt ·
$13M
T
The Valens Company
Kelowna, Canada · Biotechnology
Valens Groworks is a biotechnology company that specializes in cannabis extraction, testing, analytics, and…
Post-IPO Debt ·
$31M
G
Global Blood Therapeutics
San Francisco, United States · Biotechnology
GBT is a clinical-stage biopharmaceutical company that focuses on discovering, developing, and delivering…
Post-IPO Debt ·
$300M
E
Evolus
Irvine, United States · Biotechnology
Evolus medical aesthetics company focused on providing physicians and their patients with expanded choices in…
Post-IPO Debt ·
$125M
L
LYSOGENE
Neuilly-sur-seine, France · Biotechnology
Lysogene is a pioneer in the basic research and clinical development of gene therapy for neurodegenerative…
Post-IPO Debt ·
$4.8M
B
Biophytis
Paris, France · Biotechnology
Biophytis is a biotechnology company in the clinical stage that is dedicated to developing treatments that…
Post-IPO Debt ·
$11M
B
BridgeBio Pharma
Palo Alto, United States · Biotechnology
BridgeBio is a biotechnology company that focuses on genetic disease therapies and develops those assets with…
Post-IPO Debt ·
$750M
C
CymaBay Therapeutics
Hayward, United States · Biotechnology
CymaBay Therapeutics is a clinical-stage biopharmaceutical company located in the San Francisco Bay Area…
Post-IPO Debt ·
$75M
A
Amyris
Emeryville, United States · Biotechnology
Amyris Biotechnologies creates renewable products that focus on fuels and chemicals that provide…
Post-IPO Debt ·
$400M
V
Viracta Therapeutics
Cardiff By The Sea, United States · Biotechnology
Viracta is a precision oncology company targeting virus-associated malignancies. Viracta's proprietary…
Post-IPO Debt ·
$50M
C
Claritas Pharmaceuticals
San Rafael, United States · Biotechnology
Kalytera is pioneering the development of a next generation of cannabinoid therapeutics. Kalytera is focused…
Post-IPO Debt ·
$900k
E
Eloxx
Waltham, United States · Biotechnology
Eloxx Pharmaceuticals, an Israeli company, was founded in 2013 by Dr. Silvia Noiman and Dr. Shmuel Tuvia. As…
Post-IPO Debt ·
$30M
C
Centessa Pharmaceuticals
Cambridge, United States · Biotechnology
Centessa Pharmaceuticals is a next-generation biopharmaceutical company that aims to reshape the traditional…
Post-IPO Debt ·
$300M
S
Stealth BioTherapeutics
Newton, United States · Biotechnology
Stealth is a clinical-stage biotechnology company focused on the discovery, development and commercialization…
Post-IPO Debt ·
$25M
P
Phathom Pharmaceuticals
Florham Park, United States · Biotechnology
A biopharmaceutical business called Phathom Pharmaceuticals is dedicated to changing the way GI…
Post-IPO Debt ·
$200M
T
Taysha Gene Therapies
Dallas, United States · Biotechnology
Taysha Gene Therapies is dedicated to eliminating serious and life-threatening genetic diseases in the…
Post-IPO Debt ·
$100M
H
Harmony Biosciences
Plymouth Meeting, United States · Biotechnology
Harmony Biosciences, located in Plymouth Meeting, PA, is a pharmaceutical company that was founded in October…
Post-IPO Debt ·
$300M
D
Delcath Systems
New York, United States · Biotechnology
Delcath Systems specializes in the treatment of metastatic liver cancer through interventional oncology.…
Post-IPO Debt ·
$20M
B
Bone Therapeutics
Gosselies, Belgium · Biotechnology
Bone Therapeutics is a leading international biopharmaceutical company focused on innovative cell therapy…
Post-IPO Debt ·
$19M
Post-IPO Debt Biotechnology startup funding trends
Company size
The most common headcount band across the segment is 11-50.
Countries with the most funded Post-IPO Debt Biotechnology startups
Where funded Post-IPO Debt Biotechnology startups are headquartered, by the country on the company record.
Country
Funded startups
Where are funded Post-IPO Debt Biotechnology startups located?
Where funded Post-IPO Debt Biotechnology startups are based, by the city on the company record.
City
Funded startups
About the FundedIQ Post-IPO Debt Biotechnology startup funding data
FundedIQ tracks announced startup funding rounds and organises them by company, funding date, stage, amount, industry, location and investor. The dataset is refreshed weekly, and new rounds are normalised and de-duplicated before they are published, so the same round reported twice on different dates is recorded once.
Figures on this page cover the 90 funded Post-IPO Debt Biotechnology startups currently tracked. Round counts, capital totals and the median round are computed over a trailing 24 months. The most recent round on record for funded Post-IPO Debt Biotechnology startups is dated Oct 2022.
The table above shows the 90 most recently funded companies. Full funding histories, investor lists and founder contacts across the whole dataset open on a FundedIQ plan.
Frequently asked questions
How many funded Post-IPO Debt Biotechnology startups are there?
FundedIQ tracks 90 funded Post-IPO Debt Biotechnology startups. This page lists the 90 most recently funded of them, ordered by the date of their latest round, and the full set is available on a FundedIQ plan.
Which countries have the most funded Post-IPO Debt Biotechnology startups?
United States leads with 59 companies, ahead of Canada (12), France (5) and Germany (3).
Which cities have the most funded Post-IPO Debt Biotechnology startups?
New York leads with 6 companies, then Cambridge (5), Emeryville (3) and Fremont (2).
How often is the Post-IPO Debt Biotechnology startup funding data updated?
The dataset is refreshed weekly. New rounds are normalised and de-duplicated before they are published, and the most recent round currently on record for funded Post-IPO Debt Biotechnology startups is dated Oct 2022. Counts and totals on this page are recomputed on every refresh.
Related listings
14-day free trial · Cancel anytime
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.